secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-144217
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Q3 net loss $4.4M; 9 subjects enrolled in OPMD study; on track for BB-301 dosing in 2H2023
--------------------------------------------------------------------------------

- Net loss of $4.4M ($0.16/shr) in Q3 2023 vs $3.3M ($0.40/shr) in Q3 2022; cash $6.6M at Mar 31, 2023.
- 9 subjects enrolled in OPMD Natural History Study in the U.S.; pace supports BB-301 dosing and interim data disclosure in 2H2023.
- R&D expenses $3.17M vs $2.17M YoY, driven by GMP manufacturing and Natural History Study; operating loss $4.4M.
- Expects FDA IND response for BB-301 in Q2 2023; Canadian site activation pending REB approval.
- CEO Jerel Banks to present at OPMD International Conference in Tel Aviv on May 16, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/0001193125-23-144217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/d480708d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-144217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer